IFNG and neoplasm: On other hand, mechanisms associated with acquired resistance include the 1) loss of T cell function (i.e., mutations in IFN-γ pathway signaling), 2) lack of T cell recognition (i.e., defects on antigen presentation), 3) escape of mutation variants (i.e., loss of tumor immunogenicity), and 4) inhibitory immune checkpoints (i.e., VISTA, LAG-3, TIM-3) (16, 18).